Summary of Article: Expanding Access & Real-World Outcomes of CAR T-Cell therapy
This article from The American Journal of Managed Care details how access to CAR T-cell therapy is expanding beyond major academic centers to community oncology centers, and examines real-world outcomes at these newer facilities. Here are the key takeaways:
1. Shift in Access:
* Initially, CAR T-cell therapy was largely confined to major academic centers with FACT accreditation (rigorous quality & safety standards).
* Starting in 2023, a new wave of community oncology centers began offering the therapy, ofen before achieving FACT accreditation due to a notable backlog in the accreditation process.
2. Real-World Outcomes are Promising:
* Data from 43 patients treated at 4 new centers showed comparable outcomes to those seen at academic centers.
* Hospital stays were of similar length, especially for patients with multiple myeloma.
* 30-day readmission rates were low (under 18% for non-MM patients and under 15% for MM patients).
* No ICU admissions were reported.
3.Outpatient vs. Inpatient Treatment:
* Nearly half (47.4%) of patients were treated in an outpatient setting.
* Patients treated as outpatients, even if requiring subsequent admission, had considerably shorter hospital stays (average 12.1 days) compared to those initially treated in the hospital (average 18.8 days initial stay).
* Outpatient treatment improves patient quality of life.
4. Patient Selection for Outpatient Care:
* Accomplished outpatient treatment requires careful patient selection: patients should be relatively fit, have reliable caregivers, transportation, and nearby lodging.
* Using paid caregivers is an emerging solution for patients lacking family support, though insurance coverage remains a question.
5. Expanding Treatment to More Patients:
* Newer centers are treating patients who might have been excluded from early clinical trials, extending the therapy’s reach to a broader patient population.
* Increasing access reduces the burden of travel for patients.
in essence, the article suggests that the expansion of CAR T-cell therapy to community centers is proving to be safe and effective, with comparable outcomes to established academic centers, and a move towards more outpatient administration.
